100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43GM137621
Award Date
4/2/20
Completion Date
3/31/21
Dollars Obligated
$252K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Institute of General Medical Sciences
Awardee
Acrigen Biosciences, Inc. (GVHYYXAME436)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94710, USA
Update #1
Update #2
DISCOVERY AND APPLICATIONS OF CRISPR-CAS INHIBITOR PROTEINS
Posted 4/2/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DISCOVERY AND APPLICATIONS OF CRISPR-CAS INHIBITOR PROTEINS - ABSTRACT IN THE NEARLY 20 YEARS SINCE THE GROUNDBREAKING SEQUENCING OF THE HUMAN GENOME, THE POTENTIAL FOR PRECISION GENETIC MEDICINE HAS STILL NOT BEEN REALIZED. MORE RECENTLY, NOVEL TECHNOLOGIES SUCH AS CRISPR-CAS GENE EDITING, WHICH RELIES ON DNA-CLEAVING NUCLEASES DISCOVERED IN BACTERIA, ENABLE PRECISE ENZYMATIC EDITING OF THE HUMAN GENOME. ALTHOUGH THIS TECHNIQUE OPENS UP OPPORTUNITIES TO PREVENT OR CURE MANY DISEASES WITH UNMET MEDICAL NEED, BEFORE THIS POWERFUL TECHNOLOGY CAN BE TRANSLATED INTO MEDICAL THERAPIES IT MUST BE SHOWN TO BE NOT ONLY EFFECTIVE BUT SAFE. OFF-TARGET EDITING EVENTS WITH CRISPR-CAS SYSTEMS OCCUR DUE TO PROLONGED NUCLEASE ACTIVITY RESULTING IN UNWANTED SIDE EFFECTS OF THE GENE EDITING PROCESS, INCLUDING THE POTENTIAL FOR ONCOGENIC MUTATIONS OR CELLULAR TOXICITY. THESE SAFETY ISSUES CAN BE ADDRESSED BY DESIGNING AND IMPLEMENTING MORE EFFECTIVE WAYS TO CONTROL THE GENE EDITING PROCESS. ACRIGEN BIOSCIENCES IS DEVELOPING A SOLUTION TO BRING SAFE IN VIVO CRISPR-CAS GENE EDITING TO THE MARKET FOR THE FIRST TIME. THIS INNOVATIVE APPROACH ENCOMPASSES ROBUST ANTI-CRISPR SMALL-PROTEIN OFF-SWITCHES FOR DNA-CLEAVING NUCLEASES. THIS ROBUST AND UNIVERSAL APPROACH TO TEMPORAL CONTROL OF THE GENE EDITING PROCESS WILL BE KEY IN TRANSLATING THE POTENTIAL OF CRISPR-CAS TO THE CLINIC, AND ALIGNS WELL WITH NCATS' MISSION. THE ULTIMATE GOAL OF THIS WORK IS TO IDENTIFY PROTEINS THAT ARE EFFICACIOUS INHIBITORS OF A CAS9 ORTHOLOG IN HUMAN CELLS. THE MARKET FOR SAFE GENE EDITING APPROACHES WILL BE VERY LARGE: THE TECHNOLOGY CAN BE APPLIED TO VARIOUS MONOGENIC DISEASES, CANCERS, AND INFECTIOUS DISEASES. THE PHASE I PROJECT HAS 3 SPECIFIC AIMS. (1) ESTABLISH CELL-BASED AND IN VITRO QUANTITATIVE EXPERIMENTS TO ASSESS INHIBITION IN THE FUNCTION AND POTENCY OF A CAS9 ORTHOLOG BY (A) DEVELOPING A CANDIDATE INHIBITOR SCREENING PLATFORM AND (B) USING BIOCHEMICAL ASSAYS TO CHARACTERIZE THE MECHANISMS OF ANTI-CRISPR PROTEINS. MILESTONE: TITRATABLE NUCLEASE EXPRESSION, AS MEASURED BY WESTERN BLOT AND BACTERIOPHAGE TARGETING IN BACTERIA, LOOKING AT PHAGE REPLICATION TITERS AS A PROXY FOR CRISPR ACTIVITY. WE WILL QUANTIFY THE ACTIVITY OF CANDIDATE INHIBITORS WITH IN VITRO DNA-BINDING AND DNA-CLEAVAGE EXPERIMENTS. (2) IDENTIFY CANDIDATE ANTI-CRISPRS BY (A) DETECTING SELF-TARGETING IN BACTERIA ENCODING HOMOLOGS OF A CAS9 ORTHOLOG AND (B) IDENTIFYING BACTERIOPHAGES THAT ARE RECALCITRANT TO THE ACTION OF A CAS9 ORTHOLOG. MILESTONE: SELECT ~100 CANDIDATE PROTEINS WHICH ARE SMALL IN SIZE, ENCODED BY BACTERIAL MOBILE ELEMENTS, AND ASSOCIATED WITH KNOWN ANTI-CRISPR MARKER GENES. THE DISCOVERY WILL BE BASED ON BIOINFORMATICS AND PHAGE-BASED APPROACHES, SUCH AS PHAGE REPLICATION QUANTIFICATION WHEN TARGETED BY CRISPR. CANDIDATES TO BE TESTED IN QUANTITATIVE EXPERIMENTAL SYSTEM ESTABLISHED IN AIM 1. (3) ASSESS ANTI-CRISPR EFFICACY IN TWO HUMAN CELL LINES (HEK293T AND U2-OS-EGFP). MILESTONE: IDENTIFY 5 NON-HOMOLOGOUS PROTEINS THAT CAN INHIBIT 90% OF GENE EDITING IN MODEL HUMAN CELLS, USING A CAS9 ORTHOLOG TO EDIT GENES AT THREE DIFFERENT LOCI.
$0
6/26/21
Not listed
DISCOVERY AND APPLICATIONS OF CRISPR-CAS INHIBITOR PROTEINS - ABSTRACT IN THE NEARLY 20 YEARS SINCE THE GROUNDBREAKING SEQUENCING OF THE HUMAN GENOME, THE POTENTIAL FOR PRECISION GENETIC MEDICINE HAS STILL NOT BEEN REALIZED. MORE RECENTLY, NOVEL TECHNOLOGIES SUCH AS CRISPR-CAS GENE EDITING, WHICH RELIES ON DNA-CLEAVING NUCLEASES DISCOVERED IN BACTERIA, ENABLE PRECISE ENZYMATIC EDITING OF THE HUMAN GENOME. ALTHOUGH THIS TECHNIQUE OPENS UP OPPORTUNITIES TO PREVENT OR CURE MANY DISEASES WITH UNMET MEDICAL NEED, BEFORE THIS POWERFUL TECHNOLOGY CAN BE TRANSLATED INTO MEDICAL THERAPIES IT MUST BE SHOWN TO BE NOT ONLY EFFECTIVE BUT SAFE. OFF-TARGET EDITING EVENTS WITH CRISPR-CAS SYSTEMS OCCUR DUE TO PROLONGED NUCLEASE ACTIVITY RESULTING IN UNWANTED SIDE EFFECTS OF THE GENE EDITING PROCESS, INCLUDING THE POTENTIAL FOR ONCOGENIC MUTATIONS OR CELLULAR TOXICITY. THESE SAFETY ISSUES CAN BE ADDRESSED BY DESIGNING AND IMPLEMENTING MORE EFFECTIVE WAYS TO CONTROL THE GENE EDITING PROCESS. ACRIGEN BIOSCIENCES IS DEVELOPING A SOLUTION TO BRING SAFE IN VIVO CRISPR-CAS GENE EDITING TO THE MARKET FOR THE FIRST TIME. THIS INNOVATIVE APPROACH ENCOMPASSES ROBUST ANTI-CRISPR SMALL-PROTEIN OFF-SWITCHES FOR DNA-CLEAVING NUCLEASES. THIS ROBUST AND UNIVERSAL APPROACH TO TEMPORAL CONTROL OF THE GENE EDITING PROCESS WILL BE KEY IN TRANSLATING THE POTENTIAL OF CRISPR-CAS TO THE CLINIC, AND ALIGNS WELL WITH NCATS' MISSION. THE ULTIMATE GOAL OF THIS WORK IS TO IDENTIFY PROTEINS THAT ARE EFFICACIOUS INHIBITORS OF A CAS9 ORTHOLOG IN HUMAN CELLS. THE MARKET FOR SAFE GENE EDITING APPROACHES WILL BE VERY LARGE: THE TECHNOLOGY CAN BE APPLIED TO VARIOUS MONOGENIC DISEASES, CANCERS, AND INFECTIOUS DISEASES. THE PHASE I PROJECT HAS 3 SPECIFIC AIMS. (1) ESTABLISH CELL-BASED AND IN VITRO QUANTITATIVE EXPERIMENTS TO ASSESS INHIBITION IN THE FUNCTION AND POTENCY OF A CAS9 ORTHOLOG BY (A) DEVELOPING A CANDIDATE INHIBITOR SCREENING PLATFORM AND (B) USING BIOCHEMICAL ASSAYS TO CHARACTERIZE THE MECHANISMS OF ANTI-CRISPR PROTEINS. MILESTONE: TITRATABLE NUCLEASE EXPRESSION, AS MEASURED BY WESTERN BLOT AND BACTERIOPHAGE TARGETING IN BACTERIA, LOOKING AT PHAGE REPLICATION TITERS AS A PROXY FOR CRISPR ACTIVITY. WE WILL QUANTIFY THE ACTIVITY OF CANDIDATE INHIBITORS WITH IN VITRO DNA-BINDING AND DNA-CLEAVAGE EXPERIMENTS. (2) IDENTIFY CANDIDATE ANTI-CRISPRS BY (A) DETECTING SELF-TARGETING IN BACTERIA ENCODING HOMOLOGS OF A CAS9 ORTHOLOG AND (B) IDENTIFYING BACTERIOPHAGES THAT ARE RECALCITRANT TO THE ACTION OF A CAS9 ORTHOLOG. MILESTONE: SELECT ~100 CANDIDATE PROTEINS WHICH ARE SMALL IN SIZE, ENCODED BY BACTERIAL MOBILE ELEMENTS, AND ASSOCIATED WITH KNOWN ANTI-CRISPR MARKER GENES. THE DISCOVERY WILL BE BASED ON BIOINFORMATICS AND PHAGE-BASED APPROACHES, SUCH AS PHAGE REPLICATION QUANTIFICATION WHEN TARGETED BY CRISPR. CANDIDATES TO BE TESTED IN QUANTITATIVE EXPERIMENTAL SYSTEM ESTABLISHED IN AIM 1. (3) ASSESS ANTI-CRISPR EFFICACY IN TWO HUMAN CELL LINES (HEK293T AND U2-OS-EGFP). MILESTONE: IDENTIFY 5 NON-HOMOLOGOUS PROTEINS THAT CAN INHIBIT 90% OF GENE EDITING IN MODEL HUMAN CELLS, USING A CAS9 ORTHOLOG TO EDIT GENES AT THREE DIFFERENT LOCI.
$0
6/26/21
Not listed
DISCOVERY AND APPLICATIONS OF CRISPR-CAS INHIBITOR PROTEINS
$252.1k
4/2/20